ESMO Data Show Benefit of Approved Thyroid Cancer Regimens in Select PatientsOctober 14th 2020
Across subsets of patients with thyroid cancer, an interesting collection of research was shared with oncologists during the 2020 European Society of Medical Oncology Virtual Congress, demonstrating improvement in outcomes for patients with thyroid cancers with newer and established approved regimens.
Patient-Reported Outcomes Confirm Tolerability of Selpercatinib in RET-Driven Thyroid CancerOctober 12th 2020
In an interview with Targeted Oncology, Lori J. Wirth, MD, discussed the findings from an analysis of the patient-reported outcomes observed in the LIBRETTO-001 study of selpercatinib in patients with RET-driven thyroid cancers.
Early Data Presented for Lenvatinib and Pembrolizumab in Thyroid CancerSeptember 23rd 2020
Christine Dierks, MD, discusses the early data from a study looking at the combination of lenvatinib and pembrolizumab in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma.
Larotrectinib Induces Promising Response Rate in Patients With Differentiated Thyroid CancerSeptember 21st 2020
Larotrectinib as treatment of patients with TRK fusion-positive thyroid cancer had rapid and durable disease control, with the highest response rates observed in the differentiated thyroid cancer population.
Larotrectinib Elicits Rapid, Durable Responses in TRK Fusion-Positive Solid TumorsSeptember 20th 2020
Larotrectinib demonstrated rapid and durable as treatment of patients with TRK fusion-positive solid tumors, as well as a favorable long-term toxicity profile, according to an expanded pooled analysis from 3 clinical trials.
Ongoing ARROW Trial Data Support Pralsetinib as a Potential Treatment Option in RET-Mutant MTCSeptember 20th 2020
Patients with medullary thyroid cancer harboring abberations in RET who were treated with pralsetinib across therapy lines exhibited potent and durable clinical activity, according to results presented at the ESMO Virtual Congress 2020 from the phase 1/2 ARROW clinical trial.
Pembrolizumab/Lenvatinib Combo Achieves Promising Responses in Anaplastic Thyroid CancerSeptember 19th 2020
Christine Dierks, MD, discusses the results from the prospective phase 2 ATLEP study of lenvatinib in combination with pembrolizumab as treatment of patients with metastatic anaplastic or poorly differentiated thyroid carcinoma.
FDA Grants Priority Review to Pralsetinib for RET+ Thyroid CancersSeptember 5th 2020
The FDA has granted a priority review to pralsetinib for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer as well as for patients with RET fusion–positive thyroid cancer.
Fusion Genes Associated With More Aggressive Papillary Thyroid Cancer in Pediatric PatientsSeptember 3rd 2020
The most common genetic cause of alterations in pediatric patients with papillary thyroid cancer were fusion genes, which were associated with more aggressive disease.
Expert Highlights Major Advancements in Honor of Thyroid Cancer Awareness MonthSeptember 2nd 2020
In an interview with Targeted Oncology, Maria E. Cabanillas, MD, discussed the evolution she has observed in thyroid cancer in terms of the use of targeted therapies and other important milestones for this patient population.
Selpercatinib May Be New Standard of Care for RET-Altered Thyroid Cancers, Study ShowsAugust 26th 2020
Selpercatinib demonstrated durable efficacy as treatment of patients with medullary thyroid cancer harboring the RET mutation whether or not they received prior vandetanib or cabozantinib in the phase 1/2 LIBRETTO-001 study.